NLS Intellectual Property

IRLAB Therapeutics has announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project. “The […]

Immunovia has filed a US provisional patent application to protect the intellectual property embodied in its next-generation test to detect stage 1 and 2 pancreatic cancer. The patent application claims methods of diagnosing pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The company is seeking patent protection for the unique combination of […]

The European Patent Office (EPO) has granted a further patent in Salipro Biotech’s patent portfolio: European Patent entitled “Production of Salipro particles”. This patent covers processes related to the Salipro platform and represents a pivotal milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, […]

AlzeCure Pharma has announced that the patent offices in China, India, South Africa, Israel, Hong Kong and Mexico have granted patents covering the company’s clinical drug candidate ACD856, which is being developed against Alzheimer’s and other disorders with cognitive impairment. “This further strengthens the patent portfolio for ACD856 and is an important part of our […]

NEOGAP Therapeutics has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent strengthens NEOGAP’s strategic intellectual property portfolio and marks an important step in the company’s efforts to develop groundbreaking treatments for autoimmune diseases such as MS, it states. […]

The United States Patent and Trademark Office (USPTO) has issued US Patent covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer. The patent, titled ”Novel peptides”, provides ATOR-4066 with protection regarding methods of treating cancer and/or a tumor using a bispecific antibody comprising the complementarity-determining regions (CDRs) […]